biote Corp. Class A BTMD

Despite a 9.5% revenue decline and revised guidance, Biote Corp (BTMD) focuses on operational recovery, supply normalization, and inorganic growth opportunities.

IRVING, Texas, July 22, 2026--biote Corp. (Nasdaq: BTMD) ("Biote" or the "Company"), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners’ patients, today announced the Company will provide second quarter financial results on Wednesday, August 5, 2026, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET the same day.

The latest analyst update for biote keeps the existing price targets unchanged, signaling no revisions to where the stock is currently pegged by coverage. Even without new target moves, the story around biote does not stand still, and investors still have information to track. Ahead, you will see how to monitor shifts in the narrative so you can stay on top of what matters as new data and opinions emerge. Analyst Price Targets don't always capture the full story. Head over to our Company...

IRVING, Texas, June 01, 2026--Biote Corp. (NASDAQ: BTMD) ("Biote" or the "Company") today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026.

Moby summary of biote Corp.'s Q1 2026 earnings call

biote (NASDAQ:BTMD) executives said a voluntary recall of certain bioidentical hormone pellet inventory created a temporary but meaningful headwind in the company’s first quarter of 2026, impacting procedure revenue, margins, and salesforce productivity while management works to restore supply conti

Biote’s fair value estimate has been trimmed from US$3.17 to US$2.97 per share, signaling a tighter view on what analysts currently think the stock is worth. That change lines up with recent commentary, where many analysts are lowering price targets into a US$2 to US$3 range while balancing recall related challenges against progress on sales execution and clinic growth efforts. Read on to see how these shifting targets fit into the broader biote story and what to watch as the narrative...

biote’s modeled fair value has been trimmed from about US$4.21 to about US$3.17, a cut of roughly 25% that reflects a cooler view on what the shares may be worth today. Analysts link this reset to near term operational and growth headwinds, even as they point to stronger recent sales and EBITDA and ongoing investments aimed at future expansion. As you read on, you will see how this evolving narrative, from cautious guides to longer term themes, can shape the way you track biote from...

Moby summary of biote Corp.'s Q4 2025 earnings call

biote (NASDAQ:BTMD) used its fourth-quarter and full-year 2025 earnings call to outline changes made over the past year to its commercial organization and operating model, while also detailing near-term financial pressure tied to procedure trends, planned investments, and a voluntary recall at its A